Page 241«..1020..240241242243..250260..»

What Is Minoxidil? A Complete Guide to the Product – Mane Addicts

Posted: August 14, 2022 at 1:52 am

Minoxidil, or the active ingredient in Rogaine, has been billed as a miracle cure for hair loss. But what is it, really? And more importantly, who does it help? Hair thinning can be a painful process so we take special notice when we find something that can stop or reverse it. While weve tried the natural route (hello, rosemary oil) its not every day we find an actually clinically proven solution to hair loss. So, to learn more about this ingredient, we checked in with an expert for a guide on what it is, its side effects, benefits, and how to use it.

About the Expert

Azza Halim, M.D., is a board-certified aesthetic medicine, anti-aging, and regenerative medicine physician.

Minoxidil was originally developed to lower blood pressure in the 1960s, with a happy side effect being hair growth. It was then formulated into a topical treatment to treat hair loss in men as Rogaine, followed by a female-specific product. Board-certified physician Azza Halim, M.D. explains, It is a vasodilator medicationthat canbe taken as a pill or applied topically. This means it expandsbloodvesselsto increase flow, circulation, and add nutrients to the follicles, she continues.

The main benefit of minoxidil is restoring haireven a little bit back can be a huge confidence booster. According to Dr. Halim, minoxidil may expand the hair follicles, especially those that shrunk over time or in response to hormonal changes, which translates to more sustained growth. It also prolongs the growth phase of the hair cycle, aka the anagen phase, she notes. Minoxidil can increase hair thickness, density, and treat hair disorders like androgenetic alopecia and female pattern hair loss.

Ideal candidates are those in early stages of hair loss or thinning, says Dr. Halim. All hair types can take minoxidil, though it may be less effective on women with natural hair who have scarring from alopecia. Pregnant women cant take minoxidil, and it isnt safe for nursing mothers either. It can cause irritation when mixed with hair dye, though it can be used on color-treated hair.

As with everything there are pros and cons/side effects, Dr. Halim tells us. Side effects include scalp dryness, irritation, low blood pressure, allergic reaction, and rarelybut it is possibleto trigger interim hair loss before stimulating hair growth. Other side effects include unwanted hair growth, lightheadedness, and scalp irritation.

Minoxidil must be applied topically twice a day, says Dr. Halim. Dont expect instant gratification, however, as results take three to four months. If you stop minoxidil, be warned that hair will revert to the thickness it would have been if you didnt take it at all, not where it was when you startedthis can be a shocker. The downside is once discontinued, hair then reverts to baseline and new growth will be lost within few months, therefore, it needs maintained use, she continues. Minoxidil giveth and minoxidil taketh away.

This 2% solution is clinically proven to help fight hair loss by activating hair follicles at the scalp and extending your hairs natural growth cycle. You can even subscribe to get this product delivered to your door every month so you wont miss out on a treatment.

With a 4.2 star review from nearly 200 reviews on Ulta, its no wonder this treatment is recommended by so many. Yes, it does take about three to six months for results to show, but once they do, youll realize why it was worth the wait.

A 5% topical treatment, Rogaines four-month supply will take you to the first stages of hair regrowth.

Promote hair growth with minoxidil and refresh follicles naturally with biotin, thanks to this hair growth oil. Youll be happy to know its free of parabens, gluten, sulfates, and any other nasty ingredients that may irritate your scalp. Translation? You likely wont experience any minoxidil side effects.

Minoxidil meets DHT blocker Finasteride and Spironolactone, which slows the production of hair loss-causing hormones. People who have used this treatment have said they noticed hair regrowth in as little as one month.

Original post:
What Is Minoxidil? A Complete Guide to the Product - Mane Addicts

Posted in Regenerative Medicine | Comments Off on What Is Minoxidil? A Complete Guide to the Product – Mane Addicts

The Mugglehead technology roundup: biotechnology edition – Mugglehead

Posted: August 14, 2022 at 1:50 am

Theres usually some confusion over just what biotechnology is. For the sake of brevity, we can think of biotechnology as a broad term that applies to all practical uses of living organisms, from microorganisms like yeast used in fermentation of beer to sophisticated gene therapies.

Biotechnology involves the connection point of the natural and engineering related sciences to achieve the select application of organisms, cells, molecular analogues, and more in terms of putting together products and services. The four types of biotechnology are human, environmental, industrial, animal and plant, which we leverage to help fight hunger and disease, produce more safely, cleanly and efficiently, and work to save the environment by reducing our ecological footprint.

Here are five companies operating somewhere within the biotechnology framework.

Amgen (NASDAQ:AMGN) produced new data from its phase 1 dose exploration and expansion clinical trial for the safety and efficacy of its investigational drug tarlatamab.

Tarlatamab is a bispecific T-cell engager molecule targeting delta-like ligand3 (DLL3) in small cell lung cancer. The updated data from the ongoing trial was presented originally at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer in Vienna, Austria.

Small cell lung cancer is one of the most devastating and aggressive solid tumor cancers. The disease has lacked effective treatments with no therapies specifically approved to treat patients in the third-line setting. Our Phase 1 data for tarlatamab presented earlier today at WCLC continues to demonstrate exciting antitumor activity with remarkable response durability in heavily pre-treated patients. We are encouraged by the overall survival of 13.2 months, said David M. Reese, M.D., executive vice president of research and development at Amgen.

Amgen is one of the biggest pharmaceutical companies in the world. Its working on discovering, developing, manufacturing and delivering human therapeutics using tools like advanced human genetics to unravel diseases and understand the fundamentals of human biology. The companys specific focus is unmet medical needs and it uses its expertise to find solutions to improve health outcomes. The company has been in the biotech game since 1980 and has since grown to be recognized as one of the worlds leading and largest independent biotech companies with millions of patients around the world and a substantial medicine pipeline.

Its also one of the 30 companies that make up the Dow Jones Industrial Average and part of the NASDAQ 100 index.

What is Tarlatamab?

Tarlatamab is an investigational half-life extended bispecific T-cell engager (BiTE) molecule designed to target delta-like ligand 3 in neuroendrocrine cancers, like small cell lung cancer, and neuroendrocrine prostate cancer, both of which have neither treatments nor cures. In standard English, its a powerful cancer fighter with a lot of potential that uses BiTE technology. BiTE technoloy is a targeted immuno-oncology platform designed to engage the patients own T-cells to any tumor-specific antigen, basically getting the patients T-cells to turn on and attack the cancer.

Shares rose $0.04 to close at $248.39.

Cumberland Pharmaceuticals (NASDAQ:CPIX) released its ESG and sustainability report earlier this week.

Over the past few years as the public has started to place a lot more scrutiny on the acts and actions of companies in terms of mitigating negative externalities, ESG has become a hot button topic. For Cumberland, though, the numbers tell the tale. The company provided 2.43 million patient doses of its products in 2021 and safely disposed of 6,200 pounds of expired and damaged goods, following all the necessary waste guidelines. Beyond the numbers, though, the company had no product recalls, no products listed on the FDAs MedWatch Safety Alerts for Human Medical Products list, and no product issues singled out by the FDA from its Adverse Event Reporting System. Also, none of Cumberlands clinical trials were terminated because of failure to practice good clinical standards.

Good deal.

As the largest biopharmaceutical company founded and headquartered in the Mid-South, we understand the importance of recognizing and addressing our impact on the environment, our team members and the community. We are proud to release our third annual sustainability report, and we remain committed to building on the positive actions weve taken in these areas, said Caroline Young, Cumberland Pharmaceuticals sustainability board director.

Cumberland Pharmaceuticals is a biotechnology cum pharma-company working on the delivery of high-quality prescription brands designed to help with patient care. The company is in the business of developing, acquiring and commercializing products for the hospital acute care, gasteroenterology, rheumatology and oncology sub-sectors. The companys portfolio includes eight brands approved by the FDA. The company also has a number of Phase II clinical trials presently underway to evaluate its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Aspirin-Exacerbated Respiratory Disease and Systemic Sclerosis.

The company is focused on providing medications to improve quality of care for patients and address medical needs that have since gone unmet. Cumberland is creating solutions to help reduce costs for both healthcare providers and patients. Also, in 2021, Cumberland ate up to 60 per cent of patient prescription costs for its gastrointestinal products through a coupon program.

The company invested an average of $4,000 per full-time employee in training and development, including educational programs, initiatives for employee development and awards. Cumberlands workforce is 44 per cent women and 15 per cent of its employees are minorities. The organization also has a philanthropic arm called Cumberland Pharmaceuticals Foundation, which has donated over $33,000 to non-profit organizations in 2021.

Shares rose a penny to close at $2.45.

DNA sequencing and array-based biotechnology company, Illumina (NASDAQ:ILMN), announced that its Illumina Genomics Forum (IGF) will feature Bill Gates, who will deliver a keynote address on the potential of genomics to change global health, and then host a panel called Making Genomics for All more than a mantra, on whats needed to get genomic health out there for everyone.

Bill Gates probably doesnt need an introduction, but in the rare case he does and youve been living in a shack in Montana for the past thirty years, hes the founder and former CEO of Microsoft. After his retirement, he and his wife started the Bill and Melinda Gates Foundation, which is a nonprofit fighting inequity, disease and poverty throughout the world.

Genomics should be available to the many, not the few, and even though the genomic health era has already led to breakthrough discoveries that are advancing medical care, the benefits have not yet had a true global impact,. Through sessions led by Bill Gates and expert panelists, Illumina Genomics Forum will help attendees see and understand the path toward global health equity, said Kathryne Reeves, chief marketing officer for Illumina.

Illuminas deal is in improving human health by unlocking the power inherent in the human genome. The companys focus has been on DNA sequencing in service to customers in the research, clinical and applied markets. Its products are used in applications for the life sciences, oncology, reproductive health, agriculture and other emerging sectors.

The company previously announced that former United States President Barack Obama would be headlining the inaugural forum in a fireside chat on Wednesday, Sept. 28. Hell discuss the continued need for equity, accessibility and smart healthcare to help improve upon the human condition some twelve years after the passage of the Affordable Care Act. There will be more speakers announced in the coming weeks.

Other IGF key themes include:

IGF will take place in San Diego from September 28 through October 1.

Shares dipped $19.11 to close at $208.32.

Zynex (NASDAQ:ZYXI) announced that The Healthcare Technology Report has recognized Zynex as 33 in the Top 100 Healthcare Technology Companies of 2022.

The report provides market research, business news, updates on investment activity, as well as important corporate developments related to the healthcare technology sector. Its based in New York City and run by a team of editors, writers and media professionals embedded deep in the sector, who provide knowledgeable analysis on healthcare technology and the various companies, executives and investors that comprise the scene.

The inclusion in the Top 100 Healthcare Technology Companies of 2022 list is a testament to the focus on our mission of improving the quality of life of our patients. We are honored to be included in the ranks among some of the worlds most well-respected healthcare companies. This years list represents a wide portfolio of products and solutions, and we are humbled to know that Zynexs emphasis on innovation and patient care is being acknowledged in the life sciences community, said Thomas Sandgaard, CEO of Zynex.

Zynex has been around since 1996, and its been involved in the development, marketing and sales of medical devices for pain management and rehab, as well as a non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for hospital use. A few of the companys other offerings, and what actually managed to land them the listing, was its pain management devices and more specifically electrotherapy, bracing, hot/cold therapy, and cervical traction. These devices are primarily used in rehabilitation or orthopedic settings, helping patients recover from chronic or acute pain.

The years top 100 companies include a significant range of specialties, from genomics to pharmaceuticals, lab testing, biotechnology, therapeutics, data analysis and more.

Shares of Zynex were flat today, and closed at $9.83.

Its hard to tell whether or not Monkeypox is real or if its a media-hyped health scare. Without the data its both hard (and irresponsible) to speculate and maybe its in our best interests to treat it like it is. Kind of like COVID-19, the original strain. Deadly for some but not widely distributed. Treat it as such until proven otherwise. But you have to admit, when you follow the money there are folks out there who stand to profit from the fear the media pumps out about these diseases.

Regardless, WeTrade Group (NASDAQ:WETG), itself a tech company offering software-as-a-service (SaaS) cloud-based systems, and Jiqing Biomedical Technology decided to sign an official contract that would have WeTrade taking on the sales for Jiqings monkeypox virus test kits.

Jiqing is a Chinese medical company thats expanded its development strategy to include overseas markets, generally by offering COVID-19 antigen tests and now monkeypox kits. The company anticipates being able to benefit from the advanced tech and international market channels it picks up with WeTrade.

Working with Jiqing is not only for the profit, but it is a prominent occasion for customer base expansion. We are looking forward to attracting more customers from different industry to use our channel and private domain marketing promotion, to help them avoid the domestic competitiveness and develop overseas markets with differentiated thinking, said Pijun Liu, CEO of Wetrade.

As a global-oriented biotechnology development enterprise, Wetrade has been working on discovering overseas business for domestic companies. Wetrade believes that building its own private domain traffic would help Chinese companies carry out business operations in overseas markets easier. In the meantime, it would empower those companies to increase product awareness rapidly, find targeted audiences accurately and accumulate customers efficiently.

WeTrade Group is a technical service provider of SaaS and cloud intelligence system for micro-businesses, with a hand in the research and development for innovations and promotion for said technology. The company also developed the cloud intelligent system for micro-businesses called Ycloud. Ycloud helps with marketing and increases the payment scenario to increase customers revenue by multi-channel data statistics, AI fission and management as well as improved supply chain systems. Ycloud is presently only available in China and Hong Kong.

Shares dipped 22 per cent today and closed at $11.23.

See the original post:
The Mugglehead technology roundup: biotechnology edition - Mugglehead

Posted in Biotechnology | Comments Off on The Mugglehead technology roundup: biotechnology edition – Mugglehead

The 9th ARDD: Longevity Biotechnology Is Gaining Prominence And Credibility In The Pharmaceutical Industry – Forbes

Posted: August 14, 2022 at 1:50 am

9th ARDD: Mindjourney AI-generated image depicting a convention of scientists at the University of ... [+] Copenhagen

About eighteen years ago, when I was still a computer scientist, very few credible scientists, and entrepreneurs were interested in aging research or longevity. There were very few conferences and meetings on the topic of longevity. Venture capitalists and pharmaceutical companies were also not too keen in investing in drugs intended to increase healthy productive lifespan. The first significant conference on aging I helped organize was 2008 GTCBios New Applications of Aging Research in San Diego and it was very small less than 80 people showed up. That was one of the first high-level academia meets industry conferences. It was very difficult to find credible startup companies and there were very few credible scientists. At that conference Michael West (now at AgeX), the founder of Geron, presented his vision for BioTime (now Lineage Cell Therapeutics), Michael Rose and his team presented their work on long-lived flies, Lenny Guarente of MIT and Olivier Boss of Sirtris (later acquired by GSK) presented on sirtuin biology. So 4-5 startup companies focusing on longevity in total.

But in eighteen years, since I transitioned from IT to biotech, all of that has changed. Now, not only are there multiple conferences and meetings on longevity and aging research around the world, there is also growing interest from venture capitalists and biotechnology companies to pursue the noble cause of prolonging healthy human lifespan. Four out of the top thirty pharmaceutical companies supported by Insilico Medicine have prioritized aging research in their early-stage R&D efforts, and the more visionary and agile pharmaceutical companies have made significant progress in addressing cellular senescence. Conferences and meetings allow key opinion leaders and industry veterans to share ideas and technologies, compare research ideas, and inspire the next generation of scientists. These are just a few reasons why it is important to have conferences and meetings regularly. With coronavirus lockdowns finally coming to a halt, people are beginning to ditch virtual meetings for in-person interactions. This has led to a surge in events and conferences around the world, and scientists are finally able to meet in-person to share ideas and have open discussions. From a longevity point of view, the industry now has multiple conferences and meetings around the world, especially when compared to eighteen years ago. This years in person GRC Systems Aging conference was a major success.

AI-generated Midjourney representation of a group of scientists convening at the University of ... [+] Copenhagen

But One of the largest conferences on longevity will take place this year at the University of Copenhagen from August 29 to September 2. It is called the 9th Aging Research and Drug Discovery (ARDD) Meeting.

The ARDD meeting will feature well-known scientists and researchers from some of the biggest biotechnology companies in the world, as well as leading experts from the top academic institutions. The conference will include a longevity medicine workshop, discussions on various topics like the power of artificial intelligence, and aging of specific organs, and much, much more.

The first ARDD meeting took place in 2014, the year I founded Insilico Medicine. It started when I brought together a group of aging researchers and pharmaceutical company executives at the Aging Forum as part of the Miptec/BaselLife conference in Basel, Switzerland. The first ARDD meeting was highly successful because a lot of companies that were going to the BaselLife conference also participated in the ARDD meeting. We co-organized it with Bhupinder Bhullar or Novartis, and Brian Kennedy of the Buck Institute for several years and it was pretty successful with the many big pharmaceutical companies and startups presenting their cutting-edge research. High-level of academic speakers, interesting program, and the proximity to Roche and Novartis as well as the Basel Life conference ensured steady participation from Big Pharma and brought credibility to the conference.

But it was not until Morten Scheibye-Knudsen took over the conference and moved it to Copenhagen that the conference took off and became the largest event in aging research in the biopharmaceutical industry globally. During COVID-19 in 2020 and 2021, we arranged hybrid ARDD events, with social distancing and masks in place, and also so that people could join the event virtually. Specifically in 2021, over 160 scientists participated in the hybrid event with more than 2,000 dialing-in virtually. Within a span of 9 years, the ARDD has become the largest conference in the world on aging research and longevity. The conference costs a lot of money to arrange and we hire programmers to record the conference so that people are able to follow on YouTube. Videos from the 8th ARRD meeting can be viewed here. All the lectures from ARDD 2021 are also available online.

Group picture and statistics from the 8th Aging Research and Drug Discovery (ARDD) meeting organized ... [+] by the University of Copenhagen, Insilico Medicine, and Columbia University in 2021

This year, the ARDD is expecting over 400 people on-site, making 9th ARRD meeting one of the largest conferences in the world on longevity.

What to Expect from the 9th ARDD Meeting

Day 1: The event will begin on August 29 with a Longevity Medicine Workshop. This workshop will be the first in history to bring together health care providers involved in longevity to discuss the status quo and the future of the field, as well as related challenges, perspectives, and actionable items. The workshop is organized by Dr. Evelyne Bischof of Human Longevity Inc., with Dr. Sebastien Thuault, chief editor of Nature Aging, helping as co-organizer. Evelyn is an expert in internal medicine and oncology. Early in her career, she spent time practicing medicine and performing translational research in Switzerland, US, and China. She is the author of over 40 peer-reviewed papers. Sebastian is the launch editor of Nature Aging. He obtained his PhD from the University of Bristol and performed postdoctoral research in neuroscience at Columbia University. He joined Nature Research in 2011 and served as a senior editor at Nature Neuroscience until 2019. Following this, he transitioned to Nature Communications to steer the Neuroscience and Psychology team. In 2018, he worked as a publishing manager focusing on the proposal to launch Nature Aging and took over direction of the journal in March 2020.

Some of the other talented scientists who will be involved in this workshop include Tornado Therapeutics CEO Joan Mannick, Human Longevity CEO Wei-Wu He, Gameto CEO Dina Radenkovic, and Hevolution Foundation CEO Mehmood Khan, to name a few. I have written about Dina and Joan as part of my Women in Longevity series and also recently covered the Hevolution Foundation.

The scientists taking part in this workshop will speak on such topics as what is needed to translate geroscience into the clinic, longevity medicine therapeutics, and longevity medicine diagnostics and innovations.

Another workshop that will also take place this day is called the Emerging Tech Workshop. In this first-of-its kind workshop, we will explore the interplay between technologies that are transforming the future of biotechnology, drug discovery and aging research. This hands-on workshop will take you through the realms of blockchain, artificial intelligence, and rapid prototyping with robotics. You will also experience the power of AI and robotics to accelerate, enhance and scale scientific experiments. The Emerging Tech Workshop will be organized by Maximilan Unfried of VitaDAO. Michael Petr of Tracked.bio, Tim Peterson, co-founder of Healthspan Technologies and BIOIO, and Garri Zmudze, general partner at LongeVC will be there to lead the workshop.

The first day will also be divided into three lecture tracks, each focused on a specific area of aging research. These lecture tracks will also include time for strategic debates and open discussions.

Day 2: August 30 will begin with a talk on drugging the nutrient-sensing network by Dr. Linda Partridge of the Max Planck Institute for Biology of Aging. This will be followed by a series of talks on topics including chemical interventions in aging promoting healthspan, an update on geroscience approached to treat age-related diseases, and regulation of stem cell biology by interferons independent of antiviral function. Some of the speakers include Gordon Lithgow, Tyler Golato, Carles Canto, and Vishwa Dixit. The day will end with a talk on quantifying aging and rejuvenation by Judith Campisi of the Buck Institute. In total, there are 18 lectures scheduled just in the first day giving you an idea of what to expect next! Participants will also be able to set-up posters on this day.

Day 3: On the third day of the conference, delegates will learn about genome stability and aging, and genome maintenance mechanisms in aging by Dr. Bjorn Schumacher and Morten, respectively. These will be followed by more sessions on human biological aging. We will also learn about aging through the lens of reproductive longevity. This will also be the only time when a venture capital panel will be present to talk about investing in longevity biotechnology. Alexandra Bause, co-founder of Apollo Health Ventures, will be there to guide folks on how to get more involved in investing in longevity. Alexandra is leading the venture creation programs that aim at founding new biotech startups targeting the aging process at a molecular level. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology. Before joining Apollo, Alexandra worked with The Boston Consulting Group, specializing in biopharma strategy so if you want to start your journey as a longevity investor, you simply cannot afford to miss this one!

Day 4: The fourth day will start with new methods of target identification, biomarkers, and muscle stem cells in age and disease. We will be joined by Anders Malarstig, director at Pfizer, as well. Anders is a medical researcher and manager with experience in clinical and experimental human genetics, epidemiology and vascular biology. He is also an expert in population research and functional genomics strategies to inform drug development from preclinical phase to phase III.

Following more lectures on telomeres and circadian clocks, we will conclude the day with discussing what reprogramming, parabiosis, and autophagy have in common. Some of the speakers include Joris Deelen, Nir Barzilai, Sarah Mitchell, and Sara Hagg.

Day 5: The last day of the event will kick-off with a poster award ceremony, followed by presentations on bringing geroscience into clinical practice, predicting mortality in old age, and quantifying age and rejuvenation. The final presentation will be made by Vera Gorbunova on the topic of mechanisms of longevity and epigenome stability. The event will wrap up after this however, this is not all, theres way more!

The ARDD is Completely Non-Profit and has several unique features:

Inspire Longevity High School Students Engaging in Longevity Research

To help nurture the next generation of biogerontologists from the very early years, we are piloting the Student Ambassador Program called "Inspire Longevity". Becoming a student ambassador for the ARDD Meeting is an excellent way for students to meet with leading academic and industrial researchers and practitioners in the fields of aging and drug discovery. The student ambassador program is also an excellent way of interacting with other students from all over the world and enjoy the ARDD sessions together. PandaOmics is a platform that allows researchers a unique opportunity to both explore the unknown of OMICs data and interpret it in the context of all the scientific data generated by the scientific community. This platform will not only be showcased at ARDD 2022, but students and scientists will get a chance to explore how it works through a detailed demonstration.

Interview with the members of Inspire Longevity program - high school students planning their ... [+] careers in longevity biotechnology

The student ambassador program will be coordinated by Andrea Olsen, Zachary Harpaz, and Nina Khera. Andrea is an aspiring neurobiologist and a former intern at Insilico Medicine, while Zachary is passionate about applying AI and computer science in ways that can impact the world. Nina is currently working on a startup called Biotein, that has raised $65,000 to increase access to tools to prevent aging-related diseases. These teenagers already have impressive CVs and will be happy to guide applicants through the Inspire Longevity program.

Transparency

The two primary sources of funding for ARDD are corporate sponsorship and ticket sales for the event. Sponsorship is important to make the conferences more accessible and affordable. The finances are managed by the University of Copenhagen. The funding is distributed in three broad categories: academic speakers expense (travel expenses and overnight accommodation), on-site costs (catering, etc), and venue costs. ARDD is a non-profit with a sole aim of bringing the longevity field to the forefront of scientific research.

Supporting Ukrainian Scientists

Mindjourney AI-generated post-war recovery of Ukraine

Due to the ongoing war in Ukraine, Ukrainian scientists and researchers are invited to participate in the ARDD 2022 for free. If they cannot travel physically to the venue, they can dial-in for free and join virtually.

A screenshot of the Zoom interview with Professors Morten Scheibye-Knudsen, MD, PhD and Daniela ... [+] Bakula, MD, PhD

What To Expect from the 9th ARDD in 2022: Interview with Dr. Morten Scheibye-Knudsen and Dr. Daniela Bakula

Alex: Since you two took over the ARDD as the executive chairs and took charge of the program and organization the conference transformed into the worlds largest event in aging research in the biopharmaceutical industry. In your opinion, what were the main factors for such spectacular success?

Morten: I think we were very fortunate to be able to get leading scientist to join the meetings. We have always focused on having stellar academic speakers, including great speakers from a bit outside the field. With a great academic lineup, companies are interested in the event and this then also brings in venture capitalists.

Alex: What should we expect to see at ARDD this year? What are the hottest topics?

Daniela: I think the growing clinical focus is a very hot topic in the field. But for clinical trials to happen we need good biomarkers, so called biological clocks, and this is also a very hot topic that will be discussed by the leaders in the field. We also have the best basic scientists in the world giving us the latest on the breakthroughs in aging research that will shape the field in the coming years. I am also extremely excited about all the companies joining and the growing interest from VCs.

Alex: Most of the speakers will be on site this year. But there will be many delegates dialing in from all over the world. How would you recommend watching the lectures?

Morten: The event is streamed via a University of Copenhagen service. When you register, you will receive a link that will get you to the streaming website. BUT, if you have the possibility of coming to Copenhagen, then watching them in person is a whole other experience.

Alex: You are spending enormous amount of time and energy every week for 50 weeks in a row to get the best speakers, get the conference funded, and ensure that the people interested in aging are aware of this conference. Do you think the resulting event is worth this effort?

Daniela: This is a lot of work but also very exciting and rewarding. We hope that with this event we can contribute to foster new collaborations by bringing people from different areas and perspectives together. Also seeing that we provide a valuable knowledge and networking platform for young people with an interest in aging research makes the conference worth the effort.

Alex: Last year, around 25% of all delegates were from biopharmaceutical companies, what should we expect this year?

Morten: We currently have about 40% non-academic so the proportion of people from the industry has grown over the last years. This perhaps reflects the increasing commercial interest we have in this field.

Alex: One of the crown jewels of the pharmaceutical industry in Denmark is Novo Nordisk. In fact, it is majority-owned by a non-profit foundation. But Novo Nordisk never supported the ARDD even after it turned into the worlds largest event in its field and moved to Copenhagen. Do you know why are they ignoring it?

Morten: I think Novo Nordisk is still opening their eyes towards aging as a pharmacological target. Every year we have more and more speakers from big pharma so the field is definitely becoming very interesting for these companies and we actually do have many participants from Novo, Pfizer, Roche, and others. Hopefully we can get their support in the future.

Morten Scheibye-Knudsen, MD, PhD

Morten Scheibye-Knudsen, MD, PhD, executive chair, Aging Research and Drug Discovery (ARDD) meeting. ... [+] 8th ARDD, September, 2021

Morten Scheibye-Knudsen did his medical training at the University of Copenhagen including a short scholarship investigating mitochondrial physiology. During medical school he founded his first company, Forsoegsperson.dk, which has grown to be the largest provider of volunteers for clinical trials in Denmark. After medical school he worked as a medical doctor in Denmark and Greenland before moving to basic science as a post doctoral fellow at the National Institute on Aging, NIH, in Baltimore. Here, he utilized computational and wet lab science to investigate how DNA damage contributes to the complex phenotypes seen in premature and normal aging. In 2016 he returned to Copenhagen as an assistant professor to start his own research program focusing on aging. In 2018, he received tenure and was promoted to associate professor. His team (~20 people) utilizes computational science, animal models, gene editing, and high-throughput approaches such as high-content microscopy and omics investigations to understand the molecular basis of aging and age-associated phenotypes. Lab generated data is routinely analyzed through AI-assisted pipelines such as novel cellular senescence classifiers and fully automated animal tracking (www.tracked.bio). He has published his research in some of the best journals in the world including Cell, Cell Metabolism, New England Journal of Medicine and many others. In addition to his core research, he has been lecturing at Johns Hopkins School of Public Health for 8 years; He is a chief editor at Frontiers in Aging running the Aging Interventions section; He is an advisor to Deep Longevity, the Longevity Vision Fund and Vitexia; He has given invited presentations at top institutions (NIH, MIT, Harvard, NUS, Karolinska and others); and received several awards for his research. In addition, he has been organizing the Aging Research and Drug Discovery meeting.

Daniela Bakula, PhD

Daniela Bakula, PhD, co-chair of the Aging Research and Drug Discovery (ARDD) conference in ... [+] Copenhagen

Daniela Bakula graduated in Biology from the University of Tbingen, Germany in 2012. She obtained her PhD with the highest honors in 2017 from the University of Tbingen within the International Max-Planck Research School From Molecules to Organisms. Her PhD work focused on molecular mechanisms regulating autophagy and was awarded with highly competitive dissertation prizes. Daniela Bakula moved to Denmark in 2016, where she did her postdoc in the lab of Morten Scheibye-Knudsen at the Center for Healthy Aging, University of Copenhagen before transitioning into an assistant professorship. Her work focuses on understanding how DNA damage may impact aging. Based on her work she received a DFG fellowship as well as a Lundbeck foundation fellowship and several other grants to fund her research. She is an associate editor with Frontiers in Aging and is co-organizing ARDD since 2020.

AI-generated Midjourney representation of a group of scientists convening at the University of ... [+] Copenhagen

See the original post here:
The 9th ARDD: Longevity Biotechnology Is Gaining Prominence And Credibility In The Pharmaceutical Industry - Forbes

Posted in Biotechnology | Comments Off on The 9th ARDD: Longevity Biotechnology Is Gaining Prominence And Credibility In The Pharmaceutical Industry – Forbes

BTIG to Host Biotechnology Conference on August 8-9, 2022 – Business Wire

Posted: August 14, 2022 at 1:50 am

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will hold its annual Biotechnology Conference on Monday, August 8th and Tuesday, August 9, 2022, in New York. The firm will host over 125 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include biotech policy updates, KRAS targeting modalities, immuno-oncology, pulmonary medication development, cell therapy advancements, CNS AAV gene therapy developments, retinal disease developments, buyside biotech investor sentiment and more.

The conference will be hosted by:

Our biotechnology team has attracted some of the industrys most respected thought leaders and corporate management teams to participate in our upcoming conference, commented Ryan Serwin, CFA, Director of Research at BTIG. We look forward to producing this hybrid event, where we bring together key public and private biotechnology companies with institutional investors to explore emerging innovations and discuss impactful trends across the industry.

For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to http://www.btigresearch.com.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. With an extensive global footprint and more than 750 employees, BTIG, LLC and its affiliates operate out of 23 cities throughout the U.S., and in Europe, Asia, and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency, and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firms core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit http://www.btig.com.

Read more here:
BTIG to Host Biotechnology Conference on August 8-9, 2022 - Business Wire

Posted in Biotechnology | Comments Off on BTIG to Host Biotechnology Conference on August 8-9, 2022 – Business Wire

University of Rwanda to introduce master’s programme in biotechnology – The New Times

Posted: August 14, 2022 at 1:50 am

Officials at the University of Rwanda (UR) have said they are ready to roll out a masters degree in biotechnology, the field of study that could boost treatment of deadly diseases in the future.

This was highlighted in Kigali on Friday, August 12 at the end of weeklong deliberations about the implementation of the biotech programme, in which dozens of academics from Rwanda and foreign universities, policy makers, scientists and development partners took part.

The first cohort of candidates for the master's degree could begin their studies inearly 2023,The New Timeshas learnt.

Rwanda needs experts in biotechnology more than ever as the country embarks on developing its capacity invaccine manufacturingand genetic engineering, the officials said.

Locally trained scientists and biotech engineers could drive research in medical treatments, agriculture, foodprocessing and waste management, among other sectors.

The UR already has a bachelors programme in biotechnology. But it only offers basic skills, which are limited in terms of research and manufacturing, the officials said.

When it comes to manufacturing of vaccines or developing a nationwide industry in food processing, these are no longer fields which can be run by someone with a bachelor's degree, because they have just the foundational skills," Dr. Ignace Gatare, the Principal of UR's College of Science and Technology, toldThe New Times.

"So, with the current move to produce vaccines locally, and you have heard about the manufacturing of seeds which are resistant to climate change, it is necessary to train another highly skilled pool of professionals and that happens only at masters and PhD levels.

He added that the PhD programme would start once masters is deemed successful.

At least 834,000 (about Rwf880 million), as part of the European Unions7 million funding for capacity buildingin vaccines production in Rwanda, has been earmarked for the program to start operations.

The programme, which awaits the university senate approval, will enrol a cohort of 20-30 students, Gatare said, and could even start later this year, if everything goes according to plan.

Incorporated in three UR colleges, the programme will be hosted at the College of Science and Technology in Kigali.

According to the officials, parastatals, such as the Rwanda Biomedical Centre, Rwanda Food and Drugs Authority and Rwanda Agriculture and Animal Resources Board, will be some of the beneficiaries of the biotech programme.

Players in the Rwandan health sector have welcomed the initiative saying it would not only improve treatment of diseases but also boost research in emerging diseases.

In the 1990s, most of the diseases we treated were malaria, typhoid, meningitis and others, which are no longer prevalent, said Dr. Jean Nyirinkwaya, a long-time investor in the local health industry.

But today, there are other emerging diseases, affecting the heart, kidneys and which require better treatment or transplantation. Theres also need to carry out more research to understand why some of these diseases affect people in different categories. The masters programme in biotechnology comes at the right time.

[emailprotected]

See the original post here:
University of Rwanda to introduce master's programme in biotechnology - The New Times

Posted in Biotechnology | Comments Off on University of Rwanda to introduce master’s programme in biotechnology – The New Times

Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – The…

Posted: August 5, 2022 at 2:55 am

Viruses that cause respiratory diseases like the flu and COVID-19 can lead to mild to severe symptoms within the first few weeks of infection. These symptoms typically resolve within a few more weeks, sometimes with the help of treatment if severe. However, some people go on to experience persistent symptoms that last several months to years. Why and how respiratory diseases can develop into chronic conditions like long COVID-19 are still unclear.

I am a doctoral student working in the Sun Lab at the University of Virginia. We study how the immune system sometimes goes awry after fighting off viral infections. We also develop ways to target the immune system to prevent further complications without weakening its ability to protect against future infections. Our recently published review of the research in this area found that it is becoming clearer that it might not be an active viral infection causing long COVID-19 and similar conditions, but an overactive immune system.

Keeping your immune system dormant when there isnt an active infection is essential for your lungs to be able to function optimally.

Your respiratory tract is in constant contact with your external environment, sampling around 5 to 8 liters (1.3 to 2 gallons) of air and the toxins and microorganisms in it every minute. Despite continuous exposure to potential pathogens and harmful substances, your body has evolved to keep the immune system dormant in the lungs. In fact, allergies and conditions such as asthma are byproducts of an overactive immune system. These excessive immune responses can cause your airways to constrict and make it difficult to breathe. Some severe cases may require treatment to suppress the immune system.

During an active infection, however, the immune system is absolutely essential. When viruses infect your respiratory tract, immune cells are recruited to your lungs to fight off the infection. Although these cells are crucial to eliminate the virus from your body, their activity often results in collateral damage to your lung tissue. After the virus is removed, your body dampens your immune system to give your lungs a chance to recover.

Over the past decade, researchers have identified a variety of specialized stem cells in the lungs that can help regenerate damaged tissue. These stem cells can turn into almost all the different types of cells in the lungs depending on the signals they receive from their surrounding environment. Recent studies have highlighted the prominent role the immune system plays in providing signals that facilitate lung recovery. But these signals can produce more than one effect. They can not only activate stem cells, but also perpetuate damaging inflammatory processes in the lung. Therefore, your body tightly regulates when, where and how strongly these signals are made in order to prevent further damage.

While the reasons are still unclear, some people are unable to turn off their immune system after infection and continue to produce tissue-damaging molecules long after the virus has been flushed out. This not only further damages the lungs, but also interferes with regeneration via the lungs resident stem cells. This phenomenon can result in chronic disease, as seen in several respiratory viral infections including COVID-19, Middle East Respiratory Syndrome (MERS), respiratory syncytial virus (RSV) and the common cold.

In our review, my colleagues and I found that many different types of immune cells are involved in the development of chronic disease after respiratory viral infections, including long COVID-19.

Scientists so far have identified one particular type of immune cells, killer T cells, as potential contributors to chronic disease. Also known as cytotoxic or CD8+ T cells, they specialize in killing infected cells either by interacting directly with them or by producing damaging molecules called cytokines.

Killer T cells are essential to curbing the virus from spreading in the body during an active infection. But their persistence in the lungs after the infection has resolved is linked to extended reduced respiratory function. Moreover, animal studies have shown that removing killer T cells from the lungs after infection may improve lung function and tissue repair.

Another type of immune cells called monocytes are also involved in fighting respiratory infections, serving among the first responders by producing virus- and tissue-damaging cytokines. Research has found that these cells also continue to accumulate in the lungs of long COVID-19 patients and promote a pro-inflammatory environment that can cause further damage.

Understanding the immunological mechanisms underlying long COVID-19 is the first step to addressing a quickly worsening public health problem. Identifying the subtle differences in how the same immune cells that protect you during an active infection can later become harmful could lead to earlier diagnosis of long COVID-19. Moreover, based on our findings, my team and I believe treatments that target the immune system could be an effective approach to manage long COVID-19 symptoms. We believe that this strategy may turn out to be useful not only for COVID-19, but also for other respiratory viral infections that lead to chronic disease as well.

The rest is here:
Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The...

Posted in Stem Cells | Comments Off on Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – The…

Buffalo center fuels research that can save your life from heart disease and stroke – Buffalo News

Posted: August 5, 2022 at 2:52 am

Dr. Jennifer Lang splits most of her work life treating patients at Gates Vascular Institute and conducting research in her lab several floors up in the same building.

UB medical physics students Simon Wu and Emily Vanderbelt work with flow-through 3D-printed aneurysm models using X-rays in the Canon Stroke & Vascular Research Center, part of the University at BuffaloClinical and Translational Research Center on the Buffalo Niagara Medical Campus.

The arrangement suits her well as she continues promising research to learn if a stem cell-derived treatment can repair damaged heart tissue.

Lang, a cardiologist, and her University at Buffalo team, face a dilemma: The immune system revs into high gear when the heart suffers a serious setback, limiting the power of stem cells to heal.

The daunting task seems more surmountable these days because she works in a building filled with researchers of all stripes.

I do collaborations with groups that I otherwise wouldn't have. Its led to some really new, interesting results, said Lang, assistant professor in the UB Jacobs School of Medicine and Biomedical Sciences who practices with UBMD Internal Medicine and at the Buffalo VA Medical Center.

People are also reading

This day, a surgical team worked seamlessly to monitor her vital signs and feather a medical device through a catheter into the left side of her damaged heart. The procedure slowed her heartrate so her organs could take a couple of days to re-collect themselves and give her a fighting chance to recover.

UB-fueled research unfolds on floors five through eight of the building at 875 Ellicott St., alongside Buffalo General Medical Center.

Ten years ago, the university invested $118 million into its Clinical and Translational Research Center, and about $25 million for equipment came from industry partners who wanted to join forces with physicians, engineers and others in the science fields.

The center became the first major pieceof the UB medical school to move onto the downtown Buffalo Niagara Medical Campus, followed in late 2017 by the $375 million Jacobs School teaching and research complex, around the corner at Main and High streets.

Both foster translational medicine, which combines disciplines, resources and techniques to move benchtop research to the patient bedside, eventually strengthening community health.

Langs work symbolizes the approach.

The Buffalo native can see her high school alma mater, City Honors, from her workplace. She went to Cornell University as an undergraduate and returned to Buffalo to go to medical school. Buoyed by fellow UB students, faculty and mentors, she chose to stay in the city for her internal medicine residency and cardiology fellowship.

Lang did her classroom work and research on the UB South Campus and most of her clinical work 8 miles away, on the downtown Medical Campus.

Stairs and elevators are the only things that separate her from most of her collaborators and patients today.

I moved into this building when it opened 10 years ago, she said. At the time, I was completing my cardiology fellowship. There was a physical divide, so I was thrilled with the new arrangement. Things can happen in parallel now.

Dr. Timothy Murphy, left, director of theUB Clinical and Translational Research Center in Buffalo, works with research technician Charmaine Kirkham in their lab, which focuses on potential treatments forchronic obstructive pulmonary disease (COPD).

That was the plan, said Dr. Timothy Murphy, director of the UB Clinical and Translational Research Center.

Clinical research and health care have become more and more seamlessly integrated, he said. The building contributed to that.

Murphy, another regional native, was among those who shared and helped carry out the vision of Gates Vascular Institute founder Dr. L. Nelson Nick Hopkins III, who chaired the UB Department of Neurosurgery from 1989 to 2013 and wanted to create a more innovative vascular center.

Murphy moved his lab in 2006 from the VA Medical Center near South Campus to the UB Center for Bioinformatics and Life Sciences on the Medical Campus, so he could be involved in the design of the UB research center, on floors above Gates Vascular, as well as at the Jacobs School particularly its labs.

They always talked about physicians and researchers bumping into each other, talking to each other, and having graduate students and postdocs and technicians talk to each other, Murphy said. Having done it now for all these years, I see it really does work.

He and his research team continue a 20-year study on the bacterial infection that causes COPD in hopes it will help lead to vaccines that prevent the infection and new treatments to clear the bacteria from the lower airway.

As senior associate dean forclinical and translational researchat the Jacobs School, he is also the point person for coordinating UB-related clinical trials and encouraging collisions between health care researchers on the Medical Campus and around the world.

There were 70 such trials on the Medical Campus in 2015, when the building where he works was in its infancy. Today, there are more than 200.

"Things can happen in parallel now," says Dr. Jennifer Lang, a cardiologist, researcher and University at Buffalo assistant professor who splits her research and clinical time in the same building on the Buffalo Niagara Medical Campus.

Labs focused on obstetric and gynecological advances and keys to healthy aging occupy space near his seventh-floor lab.

The Clinical and Translational Research Center was established in 2012. UB added a biobank in 2019 to store medical specimens for ongoing clinical studies.

Its collaborative framework helped UB land a $15 million Clinical and Translational Science Awardin 2015 from the National Institutes of Health (NIH) to encourage research efforts across university departments and specialties to boost innovation, speed development of medical treatments, and reduce health disparities in poor, rural and minority communities.

The five-year grant was renewed in 2020 with nearly $22 million more, encouraging Buffalo-based researchers to work with others who got awards, including researchers with Harvard, Johns Hopkins, Stanford and Yale universities.

A printer creates a 3D model, slice by slice, at the Canon Stroke & Vascular Research Center in the University at Buffalo Clinical and Translational Research Center. Lab researchers experiment with different mixtures of six polymers to make the most malleable and useful models for medical research.

Throughout the building, the goal is to improve medical devices and treatments that make an impact in the clinics and catheter suites in the Gates Vascular Institute on the floors below the research center and provide data and education that informs others, including patients.

The eighth-floor Canon Stroke & Vascular Research Center, which tops the UB research center, is a case in point.

Ciprian Chip Ionita, its director, came to UB from Romania in 1999 and worked his first dozen years on the South Campus.

We were the first ones to move in, said Ionita, assistant professor of biomedical engineering and member of the medical school's Department of Neurosurgery.

The lab was designed to help innovate and improve medical devices and neurovascular procedures.

Part of its work involves using MRIs, CT scans and other radiological images of Gates Vascular patients to create 3D-printed models of the circulatory system and heart.

3D printing created this replica of part of a patient's spinal column at the Canon Stroke & Vascular Research Center. Researchers there push the boundaries until their findings are refined to the point where they can be applied to model-making on two highly calibrated 3D printers in the Jacobs Institute downstairs from the lab that meet FDA standards. We fail up here about 90% of the time, says Ciprian Chip Ionita, lab director. They fail maybe 1%, so were testing everything that's possible.

Medical school and other lab researchers use the models produced here to better understand how anatomy and disease of former and current patients led to poor health and, in some cases, poor surgical outcomes.

Gates Vascular surgeons also can use 3D models that replicate the anatomy of patients awaiting surgery to practice feathering catheters and medical devices through bends, nooks and crannies of the blood vessels, and deploy medical devices in spines and the circulatory system as they maneuver past muscles, bones, blockages and other obstructions that might come into play.

During practice interventions, we analyze everything, Ionita said, because we can go into these models with sensors to measure blood flow, blood pressure and more.

You can create a model that says, Here's somebody who has a carotid artery that's 50% (blocked) and he's 50 years old, Ionita said. Or we can say, 'Here is a young person in their 20s, and is fully compliant, no stenosis or whatever.' And those mechanical properties are translated by the printer.

Even cadaver donors cant do that.

The goal is to lower the rate of complications and be successful in one shot during a procedure, said Ionita, who supervises up to 10 graduate biomedical engineering students, and roughly 20 undergraduate, graduate and medical school students.

Those who pay close attention to 3D models and other medical research based on data from patients treated in the building include Dr. Elad Levy, co-director of the Gates Vascular Stroke Center; Dr. Adnan Siddiqui, director of neurological and stroke services at Kaleida Health; and Dr. Vijay Iyer, medical director of cardiology and the Structural Heart Program at Kaleida. All three have ties to UB.

Even here, Ionita said, physician-scientists and other researchers see the damage that smoking, high blood pressure and living in ZIP codes where poverty is rampant can create complications that lead to worse health and surgical outcomes.

Eric Wozniak, a senior research and development technician in the Idea to Reality lab at the Jacobs Institute, uses a microscope as he works to improve catheter technology.

Doctors and staff improve treatment protocols and surgical prowess with help from those who work on the top half of the building for UB and the Jacobs Institute. The latter is named for Dr. Lawrence D. Jacobs, a Buffalo neurosurgeon whose research led to the first treatments for multiple sclerosis.

Four years after Jacobs died in 2001, his brother Jeremy, chair of the Delaware North Cos. and the UB Council, approached the university about creating a lasting memorial for the respected physician. He later signed on to the concept of creating a multidisciplinary vascular center, starting with a $10 million donation for the institute that bears the family name.

The institute includes an atrium, caf and glass-walled spaces that overlook procedure rooms on the floor below. It has 50 employees, including more than 30 biomedical and electrical engineers, who seek company-sponsored research funding, help collect data and make prototypes for clinical trials, and work with researchers to publish their work in medical journals.

In 2016, the institute was designated a 3D Printing Center of Excellence in Health Care by Israeli-based Stratasys Ltd., a leading 3D printing-maker. In early 2018, it created a proof-of-concept Idea to Reality Center, known as i2R, to further improve medical devices and surgical techniques in the vascular space.

This is our secret sauce lab, said Siddiqui, Jacobs Institute CEO. There's nothing we do downstairs that we could not do better.

This is a device designed and built in the Idea 2 Reality lab at the Jacobs Institute in Buffalo. The lab improves medical devices and technology used in vascular procedures and treatments.

Dr. Carlos Pena, who ran the FDA Neurologic Devices Division for 15 years, joined the institute staff last year to improve the chances technology conceived and designed with help from the institute gets to market.

Every company wants to talk to him, Siddiqui said. He tells them what testing needs to be done. Some of that gets done in-house. A lot of it goes to the university or, when they have a clinical trial, that gets done downstairs so the entire ecosystem is functioning, I think better than Nick Hopkins ever imagined.

Lang, the cardiologist, doesnt miss her former workday commutes. She loves the design and location of the building that sets the standard for vascular care.

Most of her days mix benchtop research in her lab and patient visits and procedures on the floors below. When there is time, she can visit her husband, Fraser Sim, neuroscience director and associate professor at the medical school.

Because we're in such close proximity to the Jacobs School now, we're also really able to engage the medical students earlier in their careers and encourage more research, Lang said. And because we're so close to the hospital, we're able to involve medical residents and fellows in our research projects much more than ever before.

University at Buffalo medical school postdoctoral research associateToubaTarvirdizadeh focuses on cardiac research in the lab of Dr. Jennifer Lang at the UB Clinical and Translational Research Center in Buffalo.

She has spent a decade trying to find better ways for a stem cell derivative that can withstand an immune response and rejuvenate heart tissue without major complications, a result that could help patients recover from a heart attack and lessen the strain of heart failure.

Four years ago, Lang and her doctoral student researcher, Kyle Mentkowski, discovered a way that lowered the immune response in mice that received the derivative.

Mentkowski, now a post-doctorate researcher at Harvard-affiliated Massachusetts General Hospital, was talking with another group of student researchers in the building when they thought it might be a good idea to bring Dr. Jessica Reynolds, an immunologist and UB medical school associate professor, into the research.

The collaboration created robust, reproducible results in mice models, Lang said, and the start of testing in human immune cells she and her colleagues hope can benefit patients within the next decade.

Collaborators now regularly get together to chat at the Jacobs Institute.

The NIH seems very interested in this as a potential clinical therapy, Lang said, but the field as a whole is still in the beginning stages of understanding where we need to go next.

Dr. Aaron Hoffman, left, University at Buffalo medical school associate professor of surgery, and Dr. Kenneth Snyder, UB associate professor of neurosurgery, chat during a break in the Jacobs Institute atrium.

UB researchers have shared some of their findings with researchers making similar inroads elsewhere, she said, and the work spawned other collaborations with Reynolds, her research team and scientists in the UB Department of Biomedical Engineering.

This type of unplanned interaction is not a unique occurrence in this building, Lang said. Our story is just one of many.

The smart way to start your day. We sift through all the news to give you a concise, informative look at the top headlines and must-read stories every weekday.

Read the original:
Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News

Posted in Delaware Stem Cells | Comments Off on Buffalo center fuels research that can save your life from heart disease and stroke – Buffalo News

California man appears to be another person cured of HIV after a stem cell transplant – aidsmap

Posted: August 5, 2022 at 2:51 am

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the total to five, according to a presentation on Monday at the24th International AIDS Conference (AIDS 2022)in Montreal. The man remains free of HIV more than 17 months after stopping antiretroviral therapy (ART) and his leukaemia also remains in remission.

The man is older than the handful of other people previously cured after such a procedure, he has been living with HIV longer and he received a less harsh conditioning regimen prior to the transplant. This suggests that this approach may be possible for a wider subset of HIV-positive people with advanced cancer, but it is far from feasible for the vast majority of people living with HIV. Yet the case could provide clues that help researchers develop more widely applicable approaches for long-term HIV remission.

Dr Jana Dickter talks about the 'City of Hope patient' at AIDS 2022.

The City of Hope patients case, if the right donor can be identified, may open up the opportunity for more older patients living with HIV and blood cancers to receive a stem cell transplant and go into remission for both diseases, said DrJana Dickter of the City of Hope cancer centrenear Los Angeles, who described the case at the conference and at an advance media briefing last week.

The latest case involves a 66-year-old white man who was diagnosed with HIV in 1988. At one point, his CD4 count fell so low (below 100) that he was diagnosed with AIDS. He started ART when it became available in the mid-1990s. In 2018, he was diagnosed with acute myelogenous leukaemia.

Cells from which all blood cells derive. Bone marrow is rich in stem cells.

A protein on the surface of certain immune system cells, including CD4 cells. CCR5 can act as a co-receptor (a second receptor binding site) for HIV when the virus enters a host cell. A CCR5 inhibitor is an antiretroviral medication that blocks the CCR5 co-receptor and prevents HIV from entering the cell.

The disappearance of signs and symptoms of a disease, usually in response to treatment. The term is often used in relation to cancer, indicating that there is no evidence of disease, although the possibility of cancer remaining in the body cannot be ruled out. In HIV, remission is an alternative term for functional cure. A sustained ART-free remission would boost the immune system to induce long-term control of HIV, allowing a person living with HIV to maintain an undetectable viral load without daily medication.

In cell biology, a structure on the surface of a cell (or inside a cell) that selectively receives and binds to a specific substance. There are many receptors. CD4 T cells are called that way because they have a protein called CD4 on their surface. Before entering (infecting) a CD4 T cell (that will become a host cell), HIV binds to the CD4 receptor and its coreceptor.

The use of drugs to treat an illness, especially cancer.

In early 2019, at age 63, he received a stem cell transplant from an unrelated donor with a double CCR5-delta-32 mutation, which deletes the receptors most strains of HIV use to enter cells. Before the procedure, he underwent reduced-intensity conditioning chemotherapy designed for older and less fit patients, and he developed only mild graft-versus-host disease, a condition that occurs when donor immune cells attack the recipients body.

Tests showed that the man achieved 100% chimerism, meaning all his immune cells originated from the donor, Dickter reported. He continued ART (dolutegravir, tenofovir alafenamide and emtricitabine) for two years after the transplant. At that point, with a stable undetectable viral load, he and his doctors decided to try a carefully monitored treatment interruption.

More than three years after the transplant and over 17 months after stopping antiretrovirals he has no evidence of HIV RNA viral load rebound and no detectable HIV DNA in peripheral blood cells, a marker of the latent viral reservoir. Gut tissue biopsies also found no evidence of replication-competent virus.

Laboratory studies showed that his new blood cells were impervious to HIV strains that use the CCR5 receptor. However, Dickter noted that the man might remain susceptible to infection with virus that uses the alternative CXCR4 receptor, so she has counselled him about using PrEP (regular medication to prevent HIV infection).

Whats more, the man shows no detectable HIV-specific T-cell responses and his HIV antibody level has declined over time. Interestingly, he does continue to have antibodies against hepatitis B virus, even though the donor is HBV-negative.

We were thrilled to let him know that his HIV is in remission and he no longer needs to take antiretroviral therapy that he had been on for over 30 years, Dickter said in a City of Hope press release. He saw many of his friends die from AIDS in the early days of the disease and faced so much stigma when he was diagnosed with HIV in 1988. But now, he can celebrate this medical milestone.

The man, who wishes to remain anonymous, added, When I was diagnosed with HIV in 1988, like many others, I thought it was a death sentence, I never thought I would live to see the day that I no longer have HIV.

Only a small number of people have been cured of HIV after stem cell transplants. The first, Timothy Ray Brown, formerly known as the Berlin patient, received two transplants to treat leukaemia in 2006. His oncologist, DrGero Htter, came up with the idea of using stem cells with the CCR5-delta32 mutation, speculating that it might cure both cancer and HIV.

As described at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI), Brown first underwent intensive chemotherapy and whole-body radiation, and he developed near-fatal graft-versus-host disease. He stopped ART at the time of his first transplant, at age 40, but his viral load did not rebound. Researchers extensively tested his blood, gut and other tissues, finding no traces of replication-competent HIV. At the time of his death in September 2020, due to a recurrence of leukaemia, Brown had been free of HIV for more than 13 years.

A second man, Adam Castillejo, dubbed the London Patient, was also cured after receiving a stem cell transplant to treat Hodgkin lymphoma. As described at CROI 2019, he too received cells from a donor with the CCR5-delta-32 mutation, but he had less aggressive conditioning chemotherapy and developed milder graft-versus-host disease. A year and a half after the transplant, with no evidence of viable HIV, he stopped ART in September 2017, and he has now been HIV-free for more than four years.

At this years CROI, New York City researchers described a middle-aged woman with leukaemia who received a transplant using a combination of umbilical cord blood cells with the CCR5-delta-32 mutation and partially matched adult stem cells from a relative. She received intensive chemotherapy and radiation prior to the transplant but did not develop graft-versus-host disease, which is less common with cord blood. She stopped ART three years after the transplant and her viral load remains undetectable a year and a half later.

Finally, a German man, dubbed the Dsseldorf Patient, has not experienced HIV rebound more than three years after stopping ART following a CCR5-delta-32 stem cell transplant. Less is known about this case, which has not receive widespread media attention, but DrBjrn Jensen told NBC News that the man is almost definitely cured.

These cures are no longer anecdotal we now have a real case series, DrSteven Deeks of the University of California at San Francisco told aidsmap. That this approach is curative is no longer really questioned.

Researchers are still working to learn why these cures after stem cell transplantation were successful while other attempts have failed. Using stem cells with a double CCR5-delta-32 mutation seems to be key. At CROI 2012, researchers described two HIV-positive men in Boston who received stem cell transplants for cancer treatment from donors without the mutation. Both experienced viral rebound after stopping ART, though this was delayed.

Some have posited that the graft-versus-host reaction might play a role in eradicating HIV, but the five patients who were cured received different pre-transplant conditioning regimens and some experienced mild or no graft-versus-host disease.

Even as each new case provides more answers, stem cell transplants remain far too risky for people who do not need them to treat life-threatening cancer. Seeing the host as foreign, the donor immune cells can attack the recipients tissues and organs, which may necessitate immunosuppressive therapy. While waiting for donor cells to engraft, patients are highly susceptible to infections. Whats more, the procedure is medically intensive and costly and would be impossible to scale up to treat the millions of people living with HIV worldwide.

Nonetheless, each case offers clues that could help researchers develop strategies that lead to more widely applicable functional cures, or long-term remission without ART. Deeks, for example, hopes emerging gene-editing technologies might be used to delete or disable CCR5 receptors and make an individuals own immune cells resistant to HIV entry.

These cases are still interesting, still inspiring and illuminate the search for a cure, International AIDS Society president-elect DrSharon Lewin of the Peter Doherty Institute for Infection and Immunity in Melbourne told reporters during an AIDS 2022 advance media briefing.

But some advocates question why these rare cures, which wont help most people living with HIV, get so much more attention than natural or post-treatment controllers, one of whom was also described at the conference.

I think theyre selling us a bill of goods, DARE-CAB member Michael Louella said during the discussion following the presentation. Im never going to get that [a stem cell transplant], but this other type of remission that doesnt get so much attention could be applicable for more people.

Read the original here:
California man appears to be another person cured of HIV after a stem cell transplant - aidsmap

Posted in Stem Cell Therapy | Comments Off on California man appears to be another person cured of HIV after a stem cell transplant – aidsmap

Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 – Benzinga

Posted: August 5, 2022 at 2:51 am

Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.

The global induced pluripotent stem cell (iPSC) market is expected to grow from $ 2431.2 million in 2021 to $ 2640.80 million in 2022 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $ 3571.48 million in 2026 at a CAGR of 7.8%.

Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell.

Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment.

The potential risk of tumour is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy.

According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market.

ScopeMarkets Covered:1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Others2) By Application: Academic Research; Drug Development And Discovery; Toxicity Screening; Regenerative Medicine3) By End-User: Hospitals; Research Laboratories

Key Topics Covered:

1. Executive Summary

2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics

3. Induced Pluripotent Stem Cell (iPSC) Market Trends And Strategies

4. Impact Of COVID-19 On Induced Pluripotent Stem Cell (iPSC)

5. Induced Pluripotent Stem Cell (iPSC) Market Size And Growth

6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation

7. Induced Pluripotent Stem Cell (iPSC) Market Regional And Country Analysis

8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market

9. China Induced Pluripotent Stem Cell (iPSC) Market

10. India Induced Pluripotent Stem Cell (iPSC) Market

11. Japan Induced Pluripotent Stem Cell (iPSC) Market

12. Australia Induced Pluripotent Stem Cell (iPSC) Market

13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market

14. South Korea Induced Pluripotent Stem Cell (iPSC) Market

15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market

16. UK Induced Pluripotent Stem Cell (iPSC) Market

17. Germany Induced Pluripotent Stem Cell (iPSC) Market

18. France Induced Pluripotent Stem Cell (iPSC) Market

19. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market

20. Russia Induced Pluripotent Stem Cell (iPSC) Market

21. North America Induced Pluripotent Stem Cell (iPSC) Market

22. USA Induced Pluripotent Stem Cell (iPSC) Market

23. South America Induced Pluripotent Stem Cell (iPSC) Market

24. Brazil Induced Pluripotent Stem Cell (iPSC) Market

25. Middle East Induced Pluripotent Stem Cell (iPSC) Market

26. Africa Induced Pluripotent Stem Cell (iPSC) Market

27. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market

29. Induced Pluripotent Stem Cell (iPSC) Market Future Outlook and Potential Analysis

30. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mkszf2

Follow this link:
Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga

Posted in Stem Cell Therapy | Comments Off on Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 – Benzinga

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies – PR…

Posted: August 5, 2022 at 2:51 am

Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple existing and additional next generation allogeneic CAR-T programs directed to hematologic malignancies

Poseida will receive $110 million upfront, could receive up to $110 million in near-term milestones and other payments, and is eligible for future development and commercial milestones and tiered royalty payments

Poseida to host a brief conference call today at 8:30 a.m. ET

SAN DIEGO, Aug.3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

"We are excited to partner and collaborate with Roche, one of the world's largest biotechnology companies, which has a successful track record in the discovery, development and commercialization of innovative medicines," said Mark Gergen, Chief Executive Officer of Poseida. "Roche is an ideal strategic partner for Poseida with its industry-leading R&D capabilities in oncology, complementary technologies and expertise, and global regulatory and commercial capabilities. Working together, we look forward to advancing novel allogeneic cell therapies based upon Poseida's technologies for patients battling cancer."

Poseida Therapeutics announces strategic global collaboration with Roche focused on #allogeneic CAR-T cell therapies.

Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize a number of allogeneic CAR-T programs in Poseida's portfolio that are directed to hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T for the treatment of multiple myeloma and for which a Phase 1 study is underway, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for the treatment of B-cell malignancies with an IND expected in 2023. Building on complementary expertise and capabilities, the parties will also collaborate in a research program to create and develop next-generation features and improvements for allogeneic CAR-T therapies, from which they would jointly develop additional allogeneic CAR-T product candidates directed to existing and new hematologic targets. For a subset of both the Poseida portfolio programs licensed or optioned to Roche and the parties' future collaboration programs, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization. Roche will be solely responsible for the late-stage clinical development and global commercialization of all products that are subject to the collaboration.

"We are excited to partner with Poseida to further explore the potential of allogeneic cell therapies to transform cancer care by developing off-the-shelf products that can address high unmet medical needs for a broad patient population," said James Sabry, Global Head of Pharma Partnering at Roche. "Poseida's differentiated platform technologies complement our ongoing internal efforts and partnerships to discover and develop cell therapies as a next generation of medicines for patients."

Under the agreement, Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestonesand other payments in the next several years. In addition, Poseida is eligible to receive research, development, launch, and net sales milestones and other payments potentially up to $6 billion in aggregate value, as well as tiered net sales royalties into the low double digits, across multiple programs.

"We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida's unique allogeneic approach to develop CAR-T product candidates," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. "Using our proprietary technologies and manufacturing process including our booster molecule, we have the potential to develop and manufacture a product with high levels of stem cell memory T cells, which are correlated with potent antitumor efficacy in the clinic, at a scale that can potentially reach more patients and enable broad commercial use."

The effectiveness of the agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).

Poseida Therapeutics Conference Call and Webcast InformationWednesday, August 3, 2022 at 8:30 a.m. ET

Poseida's management team will host a conference call and webcast today at 8:30 a.m. ET to discuss the collaboration and Poseida's novel approach to allogeneic cell therapy. The dial-in numbers for domestic and international callers are 800-267-6316 and 203-518-9814, respectively. The conference ID number for the call is PSTX0803.

Participants may access the live webcast on the Investors & Media Section of the Poseida website, http://www.poseida.com. An archived replay of the webcast will be available for approximately 30 days following the event.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit http://www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the upfront payment and other potential fees, milestone and royalty payments and development activities under the collaboration agreement, the potential benefits of Poseida's technology platforms and product candidates, the clearance of the collaboration agreement under the HSR Act, Poseida's plans and strategy with respect to developing its technologies and product candidates, and anticipated timelines and milestones with respect to Poseida's development programs and manufacturing activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the fact that the collaboration agreement may not become effective based on HSR Act clearance, or the effectiveness may be substantially delayed, or may be terminated early, the fact that the Company will have limited control over the efforts and resources that Roche devotes to advancing development programs under the collaboration agreement and Poseida may not receive the potential fees and payments under the collaboration agreement or fully realize the benefits of the collaboration, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future preclinical and clinical results could be inconsistent with results observed to date, and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

SOURCE Poseida Therapeutics, Inc.

See more here:
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR...

Posted in Stem Cell Therapy | Comments Off on Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies – PR…

Page 241«..1020..240241242243..250260..»